Every investor in the world is crowded into the same trade.

I can't blame them. Unless you've spent 2026 under a rock with no internet connection, you've seen the power of the chip trade firsthand.

The VanEck Semiconductor ETF (SMH) is up nearly 70% year-to-date, leaving the Nasdaq in the dust, while a rabid hunt for memory has launched Micron Technology, Inc. (MU) and SanDisk Corp. (SNDK) into the stratosphere.

But here's what that crowd is missing.

While everyone stares at the chips, a group of stocks left for dead for the better part of a decade has quietly begun putting up gains of 150%, 200%, even 300% this year. Nobody wanted these names.

That's exactly why they're moving.

I'm talking about biotech — genomics, specifically. And if you know what a change of character looks like on a chart, this group is flashing the same signal the semis flashed before they became the most important trade on the market.

The next "memory trade" is right under your nose. Here's how to take advantage.

Slowly… Then Suddenly

One of the biggest clues we look for when hunting for big winners is a change in character of a stock or sector.

The semis are the textbook example.

They weren't always the dominant sector they have blossomed into during the artificial intelligence boom. I'm old enough to remember when the semis were considered boring, cyclical businesses — nowhere close to the must-own market leaders they've become.

The narrative started to flip about a decade ago, as global demand for mobile phones and crypto mining pulled in more chips than anyone expected.

Then AI poured gasoline on the fire. We've seen the memory shortage play out in 2026 as investors fight over shares of Micron, Sandisk, and the newly US-listed SK Hynix Inc. (SKHY).

But here's the part most people miss: that change of character showed up in the charts first.

Long before the financial media begins publishing daily stories on the new trend, the next big winner always tips its hand. Early buyers step in — and an unloved asset that had been stuck in neutral begins to rally.

This is exactly what we're seeing in another group of stocks right now.

The Proof Is Already on the Tape

Genomics meets every requirement for a major change in trend. These stocks are hated, ignored, and — most importantly — breaking out on both an absolute and a relative basis.

The ARK Genomic Revolution ETF (ARKG) is the perfect basket to measure the group's progress.

While many genomic leaders enjoyed strong rallies during the COVID boom that ended in 2021, these stocks then endured a brutal bear market that dragged well into 2025 — more than two years after the new bull lifted most stocks off their lows.

Then ARKG turned. The stocks that no one wanted for years staged their initial breakout in May, and have rallied more than 50% over the past four months to trigger a significant base breakout.

A 50% move in four months is impressive for any asset — for an entire ETF, it's a signal.

More importantly, ARKG is still in the very early innings of a potentially massive move. Even if it were to double from here, it would still have work to do to overtake its 2021 highs.

As the semiconductor trade consolidates, we could be looking at the next AI mega-theme unfolding right before our eyes.

And the news is only starting to catch up to the price. Just last month, Moderna's AI-designed cancer vaccine for late-stage melanoma cleared a key regulatory milestone.

Now we're hearing rumblings of other personalized cancer vaccines in development.

Moderna shares jumped 176% that day. Just imagine the excitement these stories will generate as they build — and the buying frenzies they could trigger.

The financial media is always slow to shift its coverage, especially on stocks that have been out of favor this long. But it's about to become impossible to ignore what these genomics names are doing, and I'd expect the narrative to flip hard over the next 6–12 months.

A Couple of Names to Watch

Smart money doesn't wait for the headlines. As the semiconductor and memory trades get overextended, watch for it to rotate into the highest-beta corner of healthcare — biotech and genomics.

When that rotation kicks in, you don't want to be the one chasing.

Two of ARKG's biggest holdings to keep in front of you as we start the fourth quarter:

10x Genomics Inc. (TXG) — one of ARKG's largest holdings, up more than 50% since it beat top- and bottom-line estimates last month. Shares are up more than 300% yearto-date, and — more telling — they recently cleared $65 to complete a four-year base breakout.

Twist Bioscience Corp. (TWST) — raised full-year guidance in August, and shares are up more than 60% since it reported. Another 300%-plus winner on the year, now closing in on its 2021 all-time highs near $215.

For now, both of these names belong on your watchlist.

With names like TWST and TXG already posting returns like these, the "Great Acceleration" is no longer a theory… It's a reality.

Remember, price leads the news. You're going to be hearing a lot more about these biotech themes as the news cycle sprints to catch up to the action.